To the full analysis
Buyback calculator for Lexicon Pharmaceuticals
Lexicon Pharmaceuticals stock: key metrics
LXRXLexicon Pharmaceuticals had an operating margin of −98.2% and a return on invested capital (ROIC) of −85.9% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 100.0% | −75.9% | −74.6% |
| 2007 | 100.0% | −149.6% | −117.3% |
| 2008 | 100.0% | −298.7% | −237.8% |
| 2009 | 100.0% | −840.7% | −773.6% |
| 2010 | 100.0% | −1,950.2% | −2,073.7% |
| 2011 | 100.0% | −6,170.6% | −6,285.3% |
| 2012 | −7,482.6% | −9,955.5% | −10,120.4% |
| 2013 | −3,936.1% | −4,607.2% | −4,686.1% |
| 2014 | −290.6% | −439.2% | −438.8% |
| 2015 | 26.8% | 1.1% | −3.6% |
| 2016 | −96.8% | −164.6% | −169.7% |
| 2017 | 97.9% | −151.3% | −142.9% |
| 2018 | 96.1% | −163.4% | −190.7% |
| 2019 | 99.0% | 43.9% | 40.4% |
| 2020 | 92.0% | −199.2% | −244.1% |
| 2021 | −18,371.8% | −29,224.8% | −29,449.0% |
| 2022 | −37,681.3% | −72,489.2% | −73,341.0% |
| 2023 | −4,798.0% | −14,265.0% | −14,710.9% |
| 2024 | 98.0% | −634.2% | −644.8% |
| 2025 | 99.4% | −98.2% | −101.1% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −63.5% | −38.1% | −28.5% |
| 2007 | −22.9% | −24.7% | −15.9% |
| 2008 | −41.4% | −83.6% | −29.4% |
| 2009 | −50.5% | −74.4% | −32.1% |
| 2010 | −41.2% | −25.1% | −27.7% |
| 2011 | −39.1% | −23.5% | −27.0% |
| 2012 | −41.3% | −22.4% | −29.6% |
| 2013 | 10.4% | −26.4% | −38.0% |
| 2014 | −35.3% | −22.6% | −21.3% |
| 2015 | −1.6% | 0.2% | −0.7% |
| 2016 | −89.9% | −25.2% | −29.7% |
| 2017 | −100.0% | −33.0% | −29.6% |
| 2018 | 8.2% | −28.4% | −42.4% |
| 2019 | 111.1% | 46.2% | 31.2% |
| 2020 | −37.5% | −69.2% | −28.7% |
| 2021 | −77.3% | −48.6% | −64.1% |
| 2022 | −87.0% | −55.7% | −52.5% |
| 2023 | −100.0% | −73.5% | −77.2% |
| 2024 | −100.0% | −69.0% | −67.2% |
| 2025 | −46.8% | −85.9% | −27.2% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Nov 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.